Indoco Remedies has received final approval from the United States Food & Drug Administration (USFDA) for Lacosamide Tablets USP 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat Tablets of UCB, Inc. Lacosamide Tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug. According to IQVIA sales data for the period ending January 2022, Vimpat Tablets market achieved annual sales of approximately $1.7 billion.
The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates the company’s enduring commitment to make quality and affordable generic medicines available to more patients in the United States. Its first shipment of Lacosamide Tablets has already reached US.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
